Treatment of Patients With Nephrogenic Systemic Fibrosis With Glivec
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The investigators will study the effect of imatinib mesylate (Glivec) in treatment of
moderate to severe nephrogenic systemic fibrosis (NSF).
So far there is no evidence of adequately effective treatment options of NSF. Various
treatments have been tried to stop the progressing disease. Corticosteroids, which suppress
the early inflammatory stage of the disease, fail to halt disease progression.
Other immunosuppressive agents, photopheresis, and kidney transplantations are reported to be
partly beneficial to the patients.
It has not been possible to confirm these findings in further studies because in
photopheresis, and kidney transplantation, such effects are generally unreproducible.